CDT Equity Inc. · NASDAQ:CDT
CDT Equity — Murphy Canyon Acquisition — SPAC Merger (July 2023)
30 slides from CDT Equity's SPAC merger presentation, Jul 21, 2023
Slide 1: Conduit Pharma Corporate Presentation
Conduit Pharma CORPORATE PRESENTATION July 2023
Slide 2: Disclaimer
DISCLAIMER Conduit Pharma Please note thatthe use ofthis investor presentation ['iwvestor Presentation’ is subject to certain terms andl concitions that strictly regulate its use, circulation, and copying, including any applicable confidentiality agreement. Before reading, circulating, or using the
Slide 3: Disclaimer (Cont'd)
DISCLAIMER (Cont'd) Conduit Pharma Addi In connection with the business combination, Murphy Canyon has fled @ Registration Statement on Form S-4 with the SEC (the “Registration Statement’), which includes a preliminary prospectus ane [preliminary proxy staternent. Murphy Canyon will mail a Gefinitiv
Slide 4: Table of Contents
TABLE OF CONTENTS Introduction Asset Pipeline Key Differentiators Case Study — SpringWorks Therapeutics Appendix
Slide 5: Introduction
a a (i INTRODUCTION
Slide 6: Summary
SUMMARY Conduit Pharmaceuticals Limited (“Conduit”) is a disease agnostic life science company providing an efficient Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, in co company which may shepherd their assets through Phase III, Conduit acquir
Slide 7: An Innovative Model
AN INNOVATIVE MODEL Conduit Pharma Considering the present market climate, it is evident that the pharmaceutical industry requil and innovative approach. Conduit offers a unique solution to investors through its evolution of the traditional pharma model. * Typically pharmaceutical eompanies fellow a
Slide 8: Transaction Overview
TRANSACTION OVERVIEW nduit Pharma Transaction Structure * Conduit intends to merge with Murphy Canyon Acquisition Corp. (“Murphy” publicly-listed SPAC and list on NASDAQ pursuant to the terms of a merge’ agreement * $27MM Private Investment in Public Entity (“PIPE”) committed and to be funded at clo
Slide 9: Transaction Summary
TRANSACTION SUMMARY Conduit Pharma Illustrative SPAC Cash in Trust ‘19! 23.66 Total Sources $700.66 Cash to Balance Sheet 35.93 Total Uses $700.66 Pro Forma Valuation Share Price ($/sh.) Pro Forma Shares Outstanding 26) Implied Equity Value (+) Debt (-) Pro Forma Cash Enterprise Value Pro Forma Owne
Slide 10: Key Management
KEY MANAGEMENT Conduit Pharma Dr. David Tapolezay, Chief Executive Officer Prior to joining Conduit Pharmaceuticals as Chief Executive Officer, Dr. David Tapolczay held senior leadership positions at Senior Vice President or CEO level in international R&D healthcare companies and charities with resp
Slide 11: Key Management
KEY MANAGEMENT Conduit Pharma Dr. Freda Lewis-Hall, Chair of the Board of Directors During her 35-year career in medicine, Dr. Freda Lewis-Hall served as Pfizer, Inc's Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President d
Slide 12: Asset Pipeline
Slide 13: Asset Pipeline
ASSET PIPELINE Existing Conduit Assets AZDI656 Co-Crystal pending patent applications (PCT/1B2022/000775; CA 3,180,960; and JP 2022-176753) for use in: 1. Sarcoidosis Lupus Autoimmune Hepatitis Crohn's Disease Idiopathic pulmonary fibrosis (IPF) Psoriasis Non awn ‘Type | Diabetes, Type 2 Diabetes "e
Slide 14: AZD1656 in Uveitis
AZD1656 IN UVEITIS UVEITIS Uveitis is a leading cause of blindness that affects younger working-age adults » Uveitis can also become unresponsive to treatments . Steroids, which are currently used to treat uveitis, have numerous side effects including weight gain, diabetes, increased risk of cancer
Slide 15: AZD5904 in IMI
AZD5904 IN IMI IDIOPATHIC MALE INFERTILITY (IMI) Growing condition: 485m (15%) couples globally are infertile” < We believe that, there is currently no approved pharma therapy and nothing in Phase Ii/Iil development erent assumptions aasinet cine dn Tee arte roamesonce » Significant unmet need in IM
Slide 16: Portfolio Valuation
PORTFOLIO VALUATION Conduit Pharma Murphy engaged ValueScope, Inc. to provide an opinion as to the fairness, from a financial point of view, to the stockholders of Murphy regarding the potential business combination with Conduit as of June 26, 2023. Analysis provided a fair market valuation range of
Slide 17: Key Differentiators
Slide 18: Unique Opportunity
UNIQUE OPPORTUNITY Conduit Pharma ° Conduit Pharma v Us , ian fea asial Potentially World-Renowned Innovative & Seeking to break incieased tevele basting A & Experienced Competitive IP into Dneset Areas of Efficacy for | Readily Available Industry Based Approach | _ of Clinical Need Patients Profess
Slide 19: Strategic Structure
STRATEGIC STRUCTURE Conduit Pharma x Astrazeneca > + Astra Zeneca licenses assets to St George Street Capital ("SGSC’ relationship with Conduit + Astrazeneca receives: Phase Il clinical trial with the first right of negotiation upon successful clinical trials. + Astrazeneca provides API for trials a
Slide 20: Competitive Advantage
COMPETITIVE ADVANTAGE mduit Pharma Conduit intends to d CROs. in and deliver clinical trials in a leaner and more efficient manner in collaboration with t The Conduit "Edge" EXISTING API ORMULATED. ADDITIONALLY, CONDUIT HAS ACCESS TO EXISTING ACTIVE PHARMACEUTICAL INGREDIENTS (“API”) FROM a D WHICH
Slide 21: Strategic Research & Development
STRATEGIC RESEARCH & DEVELOPMENT Conduit Pharma Conduit currently owns patent applications directed to co-crystals, which it believes are critical Intellectual Property assets that Conduit is currently seeking to patent. A patent office may consider a patent claim reciting a co-crystal to be a new c
Slide 22: Case Study
Slide 23: SpringWorks Therapeutics
SPRINGWORKS THERAPEUTICS & SpringWorks THERAPEUTICS * SpringWorks Therapeutics (“SpringWorks’) is a clinical- oncology company applyir developing and commercializing life-changing medicin: underserved patient populations. Executive Officer). SpringWorks licensed four compounds initially from Pfize c
Slide 24: Conduit Pharmaceuticals
CONDUIT PHARMACEUTICALS onduit Pharma Conduit Pharma Conduit licenses clinical assets that have already undergone Phase | testing and are ready for Phase Il testing. This allows Conduit to mitigate the risk of significant cash burn associated with failed Phas testing. By selecting assets that have a
Slide 25: Appendix
ser, APPENDIX
Slide 26: Strategic Structure
STRATEGIC STRUCTURE Conduit Pharma Conduit Pharma Astrazeneca a ca e Conduit intends to offer economic returns to investors 7] from the successful completion of clinical trials, using its comprehensive clinical expertise. AstraZeneca licences assets to SGSC and retains certain rights to license the
Slide 27: Independent Directors
INDEPENDENT DIRECTORS Dr. Freda Lewis-Hall, Chair of the Board Former Chief Medical Officer of Pfizer, Inc. + Formerly held senior positions at Bristol-Myers Squibb, Pharmacia and Eli Lilly + Board member of Milken Institute, Exact Sciences, SpringWorks Therapeutics, One Medical and others + Former
Slide 28: Non-Independent Directors
NON-INDEPENDENT DIRECTORS Conduit Pharma Dr. David Tapolezay, Chief Executive Officer Dr. Andrew Regan + Former Chief Executive Officer of Lifeare + Held senior leadership positions at AstraZeneca, GSK and Chief Executive Officer of Corvus Capital Limited + Former Chief Executive Officer and Majorit
Slide 29: Our Wider Team
OUR WIDER TEAM Wider Conduit Team Industry experienced professionals Adam Sragovicz Chief Financial Officer Jamie Chorlton ‘Adam currently serves as Chief Financial Officer of Presidio Property Trust, Inc. and Murphy Canyon. He previously served as Treasurer of Encore Capital Group, with global capi
Slide 30: Murphy Canyon Leadership Team
MURPHY CANYON LEADERSHIP TEAM Jack K. Heilbron, Chief Executive Officer & President CEO and President of Presidio Property Trust Inc. (NASDAQ: SQFT) ~ Former CEO and/or President: = NetREIT Advisors, LLC = Dubose Advisors, LLC ~ NTR Property Mgt, Inc. + Chairman and CEO of Centurion Counsel, Inc. Ad